Literature DB >> 33468224

Metabolic syndrome and esophageal cancer risk: a systematic review and meta‑analysis.

Jinjia Zhang1, Huadong Wu2, Rongying Wang3.   

Abstract

OBJECTIVE: Many clinical studies evaluating the relationship between metabolic syndrome and esophageal cancer yielded uncertain results. The purpose of this study is to systematically assess the relationship between metabolic syndrome and esophageal cancer.
METHODS: We searched clinical studies on metabolic syndrome and esophageal cancer risk in PubMed, Embase, and the Cochrane Library. Meta-analysis was conducted by RevMan 5.3 softwares.
RESULTS: A total of four cohort studies and two case-control studies met eligibility criteria and were included in the meta-analysis. Meta-analysis using a fixed-effect model indicated that MetS was related with a higher risk of EC (OR: 1.16, 95% CI 1.08-1.25). Subgroup analyses grouped by pathological types showed that MetS was related with a higher risk of EAC (OR: 1.19, 95% CI 1.10-1.28). Subgroup analyses grouped by metabolic conditions showed hyperglycemia (OR: 1.12, 95% CI 1.03-1.21),hypertension (OR: 1.23, 95% CI 1.04-1.46), obesity (OR: 1.40, 95% CI 1.22-1.60, P < 0.05) were related with a higher risk of EAC.
CONCLUSIONS: Overall, our meta-analysis provides high quality evidence that metabolic syndrome was related with a higher risk of EAC. Among the individual components of the metabolic syndrome, hyperglycemia, hypertension and obesity may be the key factors.

Entities:  

Keywords:  Esophageal cancer; Meta-analysis; Metabolic syndrome

Year:  2021        PMID: 33468224      PMCID: PMC7816502          DOI: 10.1186/s13098-021-00627-6

Source DB:  PubMed          Journal:  Diabetol Metab Syndr        ISSN: 1758-5996            Impact factor:   3.320


  47 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

Review 2.  Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling.

Authors:  Paul D Ray; Bo-Wen Huang; Yoshiaki Tsuji
Journal:  Cell Signal       Date:  2012-01-20       Impact factor: 4.315

3.  Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition.

Authors:  Annika Steffen; Matthias B Schulze; Tobias Pischon; Thomas Dietrich; Esther Molina; Maria-Dolores Chirlaque; Aurelio Barricarte; Pilar Amiano; J Ramón Quirós; Rosario Tumino; Amalia Mattiello; Domenico Palli; Paolo Vineis; Claudia Agnoli; Gesthimani Misirli; Paolo Boffetta; Rudolf Kaaks; Sabine Rohrmann; H Bas Bueno-de-Mesquita; Petra H M Peeters; Anne M May; Elizabeth A Spencer; Naomi E Allen; Sheila Bingham; Anne Tjønneland; Jytte Halkjaer; Kim Overvad; Jakob Stegger; Jonas Manjer; Björn Lindkvist; Göran Hallmanns; Roger Stenling; Eiliv Lund; Elio Riboli; Carlos A Gonzalez; Heiner Boeing
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-30       Impact factor: 4.254

4.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

5.  Metabolic syndrome and esophageal and gastric cancer.

Authors:  Yulan Lin; Eivind Ness-Jensen; Kristian Hveem; Jesper Lagergren; Yunxia Lu
Journal:  Cancer Causes Control       Date:  2015-10-08       Impact factor: 2.506

6.  The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.

Authors:  Brian Hutton; Georgia Salanti; Deborah M Caldwell; Anna Chaimani; Christopher H Schmid; Chris Cameron; John P A Ioannidis; Sharon Straus; Kristian Thorlund; Jeroen P Jansen; Cynthia Mulrow; Ferrán Catalá-López; Peter C Gøtzsche; Kay Dickersin; Isabelle Boutron; Douglas G Altman; David Moher
Journal:  Ann Intern Med       Date:  2015-06-02       Impact factor: 25.391

7.  Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006.

Authors:  Arupendra Mozumdar; Gary Liguori
Journal:  Diabetes Care       Date:  2010-10-01       Impact factor: 19.112

Review 8.  The link between the metabolic syndrome and cancer.

Authors:  Sandra Braun; Keren Bitton-Worms; Derek LeRoith
Journal:  Int J Biol Sci       Date:  2011-08-16       Impact factor: 6.580

9.  Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project.

Authors:  Björn Lindkvist; Dorthe Johansen; Tanja Stocks; Hans Concin; Tone Bjørge; Martin Almquist; Christel Häggström; Anders Engeland; Göran Hallmans; Gabriele Nagel; Håkan Jonsson; Randi Selmer; Hanno Ulmer; Steinar Tretli; Pär Stattin; Jonas Manjer
Journal:  BMC Cancer       Date:  2014-02-18       Impact factor: 4.430

10.  Metabolic Risk Profile and Cancer in Korean Men and Women.

Authors:  Seulki Ko; Seok-Jun Yoon; Dongwoo Kim; A-Rim Kim; Eun-Jung Kim; Hye-Young Seo
Journal:  J Prev Med Public Health       Date:  2016-05-18
View more
  3 in total

1.  Synergism between the metabolic syndrome components and cancer incidence: results from a prospective nested case-control study based on the China Health and Retirement Longitudinal Study (CHARLS).

Authors:  Lin Li; Fang Meng; Dongkui Xu; Lingkai Xu; Junlan Qiu; Xiaochen Shu
Journal:  BMJ Open       Date:  2022-09-17       Impact factor: 3.006

2.  Association between Hepatitis C Virus Infection and Esophageal Cancer: An Asian Nationwide Population-Based Cohort Study.

Authors:  Yin-Yi Chu; Jur-Shan Cheng; Ting-Shu Wu; Chun-Wei Chen; Ming-Yu Chang; Hsin-Ping Ku; Rong-Nan Chien; Ming-Ling Chang
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

3.  Association of Metabolic Parameter Variability with Esophageal Cancer Risk: A Nationwide Population-Based Study.

Authors:  Ji Eun Lee; Kyungdo Han; Juhwan Yoo; Yohwan Yeo; In Young Cho; Belong Cho; Hyuktae Kwon; Dong Wook Shin; Jong Ho Cho; Yong-Moon Park
Journal:  J Pers Med       Date:  2022-03-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.